Literature DB >> 32585931

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies.

Monica Mossenta1,2, Davide Busato1,2, Michele Dal Bo1, Giuseppe Toffoli1.   

Abstract

Hepatocellular carcinoma (HCC) metabolism is redirected to glycolysis to enhance the production of metabolic compounds employed by cancer cells to produce proteins, lipids, and nucleotides in order to maintain a high proliferative rate. This mechanism drives towards uncontrolled growth and causes a further increase in reactive oxygen species (ROS), which could lead to cell death. HCC overcomes the problem generated by ROS increase by increasing the antioxidant machinery, in which key mechanisms involve glutathione, nuclear factor erythroid 2-related factor 2 (Nrf2), and hypoxia-inducible transcription factor (HIF-1α). These mechanisms could represent optimal targets for innovative therapies. The tumor microenvironment (TME) exerts a key role in HCC pathogenesis and progression. Various metabolic machineries modulate the activity of immune cells in the TME. The deregulated metabolic activity of tumor cells could impair antitumor response. Lactic acid-lactate, derived from the anaerobic glycolytic rate of tumor cells, as well as adenosine, derived from the catabolism of ATP, have an immunosuppressive activity. Metabolic reprogramming of the TME via targeted therapies could enhance the treatment efficacy of anti-cancer immunotherapy. This review describes the metabolic pathways mainly involved in the HCC pathogenesis and progression. The potential targets for HCC treatment involved in these pathways are also discussed.

Entities:  

Keywords:  HCC; anticancer-immunoresponse; glucose metabolism; oxidative stress; tumor microenvironment

Year:  2020        PMID: 32585931     DOI: 10.3390/cancers12061668

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  17 in total

1.  High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma.

Authors:  Yan Tang; Xuefeng Yang; Kehai Feng; Changlu Hu; Suyi Li
Journal:  J Gastrointest Oncol       Date:  2021-02

2.  Radiation-Induced Metabolic Shifts in the Hepatic Parenchyma: Findings from 18F-FDG PET Imaging and Tissue NMR Metabolomics in a Mouse Model for Hepatocellular Carcinoma.

Authors:  Yi-Hsiu Chung; Cheng-Kun Tsai; Ching-Fang Yu; Wan-Ling Wang; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen; Gigin Lin
Journal:  Molecules       Date:  2021-04-28       Impact factor: 4.411

3.  Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma.

Authors:  Miaomiao Li; Juntao Hu; Riming Jin; Hongxia Cheng; Huaping Chen; Limin Li; Kun Guo
Journal:  J Hepatocell Carcinoma       Date:  2020-12-08

4.  Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma.

Authors:  Dan Chen; Xiaoting Li; Hui Li; Kai Wang; Xianghua Tian
Journal:  J Oncol       Date:  2022-01-04       Impact factor: 4.375

5.  Novel lncRNA AL033381.2 Promotes Hepatocellular Carcinoma Progression by Upregulating PRKRA Expression.

Authors:  Feiran Wang; Lirong Zhu; Qiang Xue; Chong Tang; Weidong Tang; Nannan Zhang; Chen Dai; Zhong Chen
Journal:  Oxid Med Cell Longev       Date:  2022-01-07       Impact factor: 6.543

6.  Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma.

Authors:  Wei Wang; Zhenfeng Deng; Zongrui Jin; Guolin Wu; Jilong Wang; Hai Zhu; Banghao Xu; Zhang Wen; Ya Guo
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

7.  LDH and GGT/ALT Ratio as Novel Prognostic Biomarkers in Hepatocellular Carcinoma Patients after Liver Transplantation.

Authors:  Qi Zhang; Xingyuan Jiao
Journal:  Comput Math Methods Med       Date:  2021-11-20       Impact factor: 2.238

Review 8.  Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.

Authors:  Danyu Du; Chan Liu; Mengyao Qin; Xiao Zhang; Tao Xi; Shengtao Yuan; Haiping Hao; Jing Xiong
Journal:  Acta Pharm Sin B       Date:  2021-09-25       Impact factor: 11.413

Review 9.  New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics.

Authors:  Ya-Ling Yang; Yen-Hsiang Chang; Chia-Jung Li; Ying-Hsien Huang; Ming-Chao Tsai; Pei-Yi Chu; Hung-Yu Lin
Journal:  J Pers Med       Date:  2021-03-18

10.  Glucose Activates Lysine-Specific Demethylase 1 through the KEAP1/p62 Pathway.

Authors:  Chiao-Yun Lin; Chen-Bin Chang; Ren-Chin Wu; Angel Chao; Yun-Shien Lee; Chi-Neu Tsai; Chih-Hao Chen; Chih-Feng Yen; Chia-Lung Tsai
Journal:  Antioxidants (Basel)       Date:  2021-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.